10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
10x Genomics, Inc. filed a Current Report on Form 8-K dated December 12, 2019. The filing provides Regulation FD disclosure regarding the company’s ongoing patent dispute with Bio-Rad Laboratories, Inc. and Lawrence Livermore National Security, LLC before the U.S. International Trade Commission (ITC). It is not a periodic financial report.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material Developments
- The ITC investigation concerns allegations that substantially all of 10x Genomics’ products infringe five Bio-Rad patents.
- A September 2018 Initial Determination found that the company’s GEM microfluidic chips directly infringed three patents: U.S. Patent Nos. 9,500,664, 9,636,682, and 9,649,635.
- The Initial Determination found that the company’s gel bead manufacturing microfluidic chip and Next GEM microfluidic chip did not infringe the asserted claims identified in the determination.
- The presiding judge recommended an exclusion order and cease-and-desist order relating to imported GEM microfluidic chips.
- The ITC is reviewing certain findings concerning indirect infringement and infringement involving the company’s gel bead manufacturing and Next GEM microfluidic chips.
- On December 12, 2019, the ITC extended the target date for completing its investigation to December 18, 2019. A Final Determination was expected on or before that date.
Outlook, Risks, and Unusual Items
The primary disclosed risk is the potential impact of an ITC exclusion order or cease-and-desist order on the company’s ability to import or sell affected GEM microfluidic chips. The filing does not state the expected financial impact, probability of an adverse final determination, potential remedies beyond those described, or any contingency plans.
Key Facts to Verify
- Verify the ITC’s Final Determination issued on or before December 18, 2019.
- Confirm whether any exclusion order or cease-and-desist order was entered and which products were affected.
- Assess any subsequent appeals, settlements, redesigns, licensing arrangements, or other developments involving the patents.
- Review later SEC filings for quantified financial or operational effects of the ITC proceeding.